« Return to News | Clinical Intelligence

Sanofi/Regeneron's aflibercept fails trial

Thursday, March 17, 2011 01:06 PM

Sanofi-aventis and partner Regeneron have suffered a setback with their investigational agent aflibercept failing a late-stage trial for non-small cell lung cancer (NSCLC), according to PharmaTimes.

Top-line data from the 913-patient phase III VITAL trial evaluating aflibercept (also known as VEGF Trap) for the second-line treatment of NSCLC showed that adding the drug to the chemotherapy docetaxel did not meet the primary endpoint of improvement in overall survival compared with docetaxel plus placebo. However, the addition of aflibercept to docetaxel demonstrated activity as measured by secondary endpoints, i.e., progression-free survival and an overall objective response rate (ORR) of 23.3% in the aflibercept arm compared to 8.9% for the placebo/chemotherapy combo.

The companies said they will conduct a detailed analysis of the efficacy and safety results of VITAL and present full results at an upcoming medical meeting.

Debasish Roychowdhury, head of oncology at Sanofi, said, "bringing new and innovative cancer therapies to patients can be incredibly challenging, especially in difficult-to-treat cancers such as second-line NSCLC.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.